ABBV stock has seen strong gains of 85% from levels of $90 in early January 2021 to around $165 now, vs. an increase of about ...

Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Johnson & Johnson (NYSE:JNJ) is about to trade ex-dividend in the next 3 days. The ex-dividend ...

Notably, the $205 average of analysts’ price estimate for ABBV, reflects over 20% upside from its current levels of around $165. While ABBV stock may outperform JNJ stock in the next three years ...

J&J JNJ stock has plunged 6.1% in a month, losing almost $24 billion of its market value. Though slowing sales in its MedTech ...

Johnson & Johnson faces uncertainty with speculation about RFK Jr. at HHS. Learn why JNJ stock remains a buy despite ...

On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $152.64 which represents a decrease of $-2.40 or -1.55% from the prior close of $155.04. The stock opened at $154.53 and ...

On Tuesday, Johnson & Johnson (JNJ) stock saw a decline, ending the day at $153 which represents a decrease of $-1.77 or -1.14% from the prior close of $154.77. The stock opened at $153.95 and touched ...

Leerink Partners analyst David Risinger has maintained their bullish stance on JNJ stock, giving a Buy rating on November 14.Don't Miss our ...

JOHNSON & JOHNSON (JNJ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating using this strategy is 81% based on the firm’s underlying fundamentals and the stock’s ...

During market volatility and economic downturns, investors often turn to stocks offering stable dividends and growth ...